BCV
VRDN icon

Banque Cantonale Vaudoise’s Viridian Therapeutics VRDN Stock Holding History

Banque Cantonale Vaudoise’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-3,333
Closed -$55K – 1194
2020
Q4 		$55K Hold
3,333
– – ﹤0.01% 927
2020
Q3 		$39K Buy
+3,333
New +$49.7K ﹤0.01% 927

Other funds holding VRDN

ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
AVA
Atlas Venture Advisors Boston, Massachusetts $122M AUM 26.28% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Banque Cantonale Vaudoise's VRDN Position: Q1 2021 in Review

Banque Cantonale Vaudoise sold out of Viridian Therapeutics (VRDN) in Q1 2021, closing a stake of 3,333 shares — an estimated $55K sold.

Banque Cantonale Vaudoise first reported a position in VRDN in Q3 2020 and held it in 2 quarters. The position peaked at $55K in Q4 2020. 33 funds tracked by Wall St. Rank hold VRDN as of Q1 2021.

  • Banque Cantonale Vaudoise reported no remaining Viridian Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Banque Cantonale Vaudoise sold 3,333 Viridian Therapeutics shares in Q1 2021, an estimated $55K.
  • Banque Cantonale Vaudoise first reported a position in Viridian Therapeutics in Q3 2020 and held it in 2 quarters.
  • Banque Cantonale Vaudoise's Viridian Therapeutics position peaked at $55K in Q4 2020.
  • 33 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2021.

Based on Banque Cantonale Vaudoise's 13F filing for Q1 2021, filed 11 May 2021.